特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
662983

勃起障害治療薬市場:世界の業界分析、規模、シェア、成長、動向、予測

Erectile Dysfunction Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

出版日: | 発行: Transparency Market Research | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
勃起障害治療薬市場:世界の業界分析、規模、シェア、成長、動向、予測
出版日: 2018年06月05日
発行: Transparency Market Research
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の勃起障害治療薬市場について調査し、市場の現状と成長予測、薬剤別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 序論

第2章 仮定と調査方法

第3章 エグゼクティブサマリー

第4章 市場概要

  • イントロダクション
  • 概要

第5章 市場見通し

  • 市場動向
    • 促進因子
    • 阻害因子
    • 機会
    • 機会分析
    • 動向
  • 市場分析と予測
  • ポーターズファイブフォース分析
  • 市場価値チェーン分析
  • パイプライン分析
  • 今後の見通し

第6章 薬剤別市場分析と予測

  • イントロダクションと定義
  • 調査結果/発展
  • 市場価値予測
  • 市場予測
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra
  • 市場の魅力度

第7章 流通チャネル別市場分析と予測

  • イントロダクションと定義
  • 調査結果/発展
  • 市場価値予測
  • 市場予測
    • 院内薬局
    • 小売薬局
    • オンライン薬局
  • 市場の魅力度

第8章 地域別市場

  • 主な調査結果
  • 市場価値予測
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力度

第9章 北米

第10章 欧州

第11章 アジア太平洋地域

第12章 ラテンアメリカ

第13章 中東・アフリカ

第14章 競合環境

  • 市場参入企業
  • 企業別市場シェア分析
  • 競合ビジネス戦略
  • 企業プロファイル
図表

List of Tables:

  • Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2016-2026
  • Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 9: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 19: Pfizer, Inc. Products Offered
  • Table 20: Pfizer, Inc. Recent Developments
  • Table 21: Dong-A ST Co., Ltd. Products Offered
  • Table 22: Dong-A ST Co., Ltd. Recent Developments
  • Table 23: Eli Lilly and Company Products Offered
  • Table 24: Eli Lilly and Company Recent Developments
  • Table 25: Bayer AG Products Offered
  • Table 26: Bayer AG Recent Developments
  • Table 27: VIVUS, INC. Ltd. Products Offered
  • Table 28: VIVUS, INC. Recent Developments
  • Table 29: SK chemicals Products Offered
  • Table 30: SK chemicals Recent Developments
  • Table 31: Meda Pharmaceuticals Inc. Products Offered
  • Table 32: Meda Pharmaceuticals Inc. Recent Developments
  • Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered
  • Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments
  • Table 35: Apricus Biosciences, Inc. Products Offered
  • Table 36: Apricus Biosciences, Inc. Recent Developments
  • Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

List of Figures:

  • Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2016-2026
  • Figure 02: Market Value Share, by Drug Class (2017)
  • Figure 04: Market Value Share, by Distribution Channel (2017)
  • Figure 05: Market Value Share, by Region (2017)
  • Figure 06: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2016-2026
  • Figure 08: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2016-2026
  • Figure 9: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2016-2026
  • Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2016-2026
  • Figure 11: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2016-2026
  • Figure 12: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2017 and 2026
  • Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2016-2026
  • Figure 14: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2016-2026
  • Figure 15: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2016-2026
  • Figure 16: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2017 and 2026
  • Figure 17: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2026
  • Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 20: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2026
  • Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 23: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 24: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 25: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 28: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 32: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 36: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 37: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2017)
  • Figure 38: Pfizer, Inc. Breakdown of Net Sales, by Region, 2016
  • Figure 39: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 40: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 41: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment
  • Figure 42: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2016
  • Figure 43: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 44: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 45: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 46: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2016
  • Figure 47: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2016
  • Figure 48: Bayer AG Breakdown of Net Sales, by Region, 2017
  • Figure 49: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2017
  • Figure 50: Bayer AG R&D Intensity and Net Income (US$ Mn) - Company Level, 2016-2017
  • Figure 51: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 52: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2017
  • Figure 53: VIVUS, INC. Breakdown of Research and Development Expenses, 2017
  • Figure 54: SK chemicals Consolidated Balance Sheet (US$ Bn), 2016
  • Figure 55: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017
  • Figure 56: SK chemicals R&D Intensity and Net Income (US$ Mn) - Company Level, 2014-2016
  • Figure 57: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2015
  • Figure 58: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2011-2015
  • Figure 59: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) - Company Level, 2014-2015
  • Figure 60: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 61: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 62: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) - Company Level, 2015-2016
  • Figure 63: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 64: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) - Company Level, 2015-2016
  • Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
  • Figure 66: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016
目次

Title:
Erectile Dysfunction (ED) Drugs Market (Drug - Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Erectile Dysfunction (ED) Drugs Market - Overview

This report studies the current as well as future prospects of the global erectile dysfunction (ED) drugs market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and marketing of therapeutic drugs for the treatment of erectile dysfunction, as well as new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global erectile dysfunction drugs market with respect to the leading segments based on drug class, distribution channel, and region.

The global erectile dysfunction drugs market has been segmented based on drug, distribution channel, and region. In terms of drug, the market has been classified into Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and others. Based on distribution channel, the global erectile dysfunction drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of erectile dysfunction. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the global erectile dysfunction drugs market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global erectile dysfunction drugs market.

Geographically, the global erectile dysfunction drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global erectile dysfunction drugs market.

Major players operating in the global erectile dysfunction drugs market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, VIVUS, Inc., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Teva Pharmaceutical Industries Ltd.

The global erectile dysfunction drugs market has been segmented as follows:

Global Erectile Dysfunction Drugs Market, By Drug

  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others

Global Erectile Dysfunction Drugs Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Erectile Dysfunction Drugs Market, By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Segmentation
  • 1.2. Key Research Objectives
  • 1.3. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Secondary Research Methodology
  • 2.2. Primary Research Methodology
  • 2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview

5. Market Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Opportunity Analysis
    • 5.1.5. Trends
  • 5.2. Global Erectile Dysfunction Market Analysis and Forecasts, 2016-2026
  • 5.3. Porter's Five Forces Analysis
  • 5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
  • 5.5. Pipeline Analysis
    • 5.5.1. Discovery
    • 5.5.2. Preclinical
    • 5.5.3. IND (Investigational New Drug)
    • 5.5.4. Phase I
    • 5.5.5. Phase I/II
    • 5.5.6. Phase II
    • 5.5.7. Phase III
    • 5.5.8. Pre-registration
  • 5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Drug

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug, 2016-2026
    • 6.3.1. Viagra
    • 6.3.2. Cialis
    • 6.3.3. Staxyn/Levitra
    • 6.3.4. Stendra/Spedra
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Country/Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug, 2016-2026
    • 9.2.1. Viagra
    • 9.2.2. Cialis
    • 9.2.3. Staxyn/Levitra
    • 9.2.4. Stendra/Spedra
    • 9.2.5. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Value Forecast, by Country, 2016-2026
    • 9.4.1. U.S.
    • 9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug, 2016-2026
    • 10.2.1. Viagra
    • 10.2.2. Cialis
    • 10.2.3. Staxyn/Levitra
    • 10.2.4. Stendra/Spedra
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2.Market Value Forecast, by Drug, 2016-2026
    • 11.2.1. Viagra
    • 11.2.2. Cialis
    • 11.2.3. Staxyn/Levitra
    • 11.2.4. Stendra/Spedra
    • 11.2.5. Others
  • 11.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.3.1. Hospital Pharmacy
    • 11.3.2. Retail Pharmacy
    • 11.3.3. Online Pharmacy
  • 11.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2.Market Value Forecast, by Drug, 2016-2026
    • 12.2.1. Viagra
    • 12.2.2. Cialis
    • 12.2.3. Staxyn/Levitra
    • 12.2.4. Stendra/Spedra
    • 12.2.5. Others
  • 12.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.3.1. Hospital Pharmacy
    • 12.3.2. Retail Pharmacy
    • 12.3.3. Online Pharmacy
  • 12.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2.Market Value Forecast, by Drug, 2016-2026
    • 13.2.1. Viagra
    • 13.2.2. Cialis
    • 13.2.3. Staxyn/Levitra
    • 13.2.4. Stendra/Spedra
    • 13.2.5. Others
  • 13.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.3.1. Hospital Pharmacy
    • 13.3.2. Retail Pharmacy
    • 13.3.3. Online Pharmacy
  • 13.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis, by Company (2017)
  • 14.3. Competitive Business Strategies
  • 14.4. Company Profiles
    • 14.4.1. Pfizer, Inc.
      • 14.4.1.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.1.2. Product Portfolio
      • 14.4.1.3. SWOT Analysis
      • 14.4.1.4. Strategic Overview
    • 14.4.2. Dong-A ST Co., Ltd.
      • 14.4.2.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.2.2. Product Portfolio
      • 14.4.2.3. SWOT Analysis
      • 14.4.2.4. Strategic Overview
    • 14.4.3. Eli Lilly and Company
      • 14.4.3.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.3.2. Product Portfolio
      • 14.4.3.3. SWOT Analysis
      • 14.4.3.4. Strategic Overview
    • 14.4.4. Bayer AG
      • 14.4.4.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.4.2. Product Portfolio
      • 14.4.4.3. SWOT Analysis
      • 14.4.4.4. Strategic Overview
    • 14.4.5. VIVUS, INC.
      • 14.4.5.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.5.2. Product Portfolio
      • 14.4.5.3. SWOT Analysis
      • 14.4.5.4. Strategic Overview
    • 14.4.6. SK chemicals
      • 14.4.6.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.6.2. Product Portfolio
      • 14.4.6.3. SWOT Analysis
      • 14.4.6.4. Strategic Overview
    • 14.4.7. Meda Pharmaceuticals Inc.
      • 14.4.7.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.7.2. Product Portfolio
      • 14.4.7.3. SWOT Analysis
      • 14.4.7.4. Strategic Overview
    • 14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
      • 14.4.8.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.8.2. Product Portfolio
      • 14.4.8.3. SWOT Analysis
      • 14.4.8.4. Strategic Overview
    • 14.4.9. Apricus Biosciences, Inc.
      • 14.4.9.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.9.2. Product Portfolio
      • 14.4.9.3. SWOT Analysis
      • 14.4.9.4. Strategic Overview
    • 14.4.10. Teva Pharmaceutical Industries Ltd.
      • 14.4.10.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.10.2. Product Portfolio
      • 14.4.10.3. SWOT Analysis
      • 14.4.10.4. Strategic Overview
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.